Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cara Therapeutics shares | $12.56

Own Cara Therapeutics shares in just a few minutes.

Cara Therapeutics logo

About our promoted products: Our 'promoted' products are presented as a result of a commercial advertising arrangement or to highlight a particular feature. Promoted products are not a recommendation, an indication a product is the best in its category, nor represent all products in the market. It is important to compare your options and find the right product for you. Some of our promoted products are CFD providers. CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment

How to buy shares in Cara Therapeutics from New Zealand

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cara Therapeutics Find the stock by name or ticker symbol: CARA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cara Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Cara Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cara Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare trading platforms

Name Product Available Investment Types Min. Monthly Fee Currency Conversion Fee Available Markets
Hatch
Shares, ETFs
$0
0.5%
NASDAQ, NYSE
Invest in more than 4,100 US companies and exchange-traded funds (ETFs). No minimum investment or monthly fees.
Stake
Shares, ETFs
$0
1% ($2 min)
NASDAQ, NYSE, BATS, Chicago Stock Exchange, and more
Sign up through Finder and use referral code "FINDERNZ" for a free stock. Trade more than 3,800 US-listed stocks and ETFs through Stake with $0 fees on trades.
Sharesies
Shares, ETFs, Managed Funds, Index Funds
$0
0.4%
ASX, NASDAQ, NYSE, NZX, CBOE
Trade and invest in more than 3,000 companies, ETFs and managed funds across New Zealand, the US and Australia.
loading

Compare up to 4 providers

Important: By investing in a share CFD, you are speculating on the price movement of that share and do not have ownership of the underlying asset. CFDs are complicated financial products are are more suited to experienced trader. Learn more about CFD trading
Name Product Minimum Opening Deposit Minimum Opening Deposit Commission Available Markets Platforms
Plus500 CFD
NZ 100
100
No commission
Indices, FX, Shares, Commodities, Cryptocurrency, ETFs, Options
Plus500 WebTrader
CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment.
Finder exclusive offer: Open a new trading account and receive a welcome bonus of NZ$120 when you deposit your first $400 and enter the bonus code “Special200”. Ts&Cs apply.
Trade CFDs on shares, forex, crypto, indices, commodities and more.
BlackBull Markets CFD
USD 200
200
No commission
Indices, FX, Commodities, Precious metals
MetaTrader 4, MetaTrader 5
CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment.
Trade CFDs on shares, forex, indices, commodities, precious metals and more.
IG Markets CFDs
AUD 0
0
0.08% with $7 minimum
Indices, FX, Shares, Commodities, Cryptocurrency, Options, ETPs
MetaTrader 4, ProRealTime
CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment.
Trade from over 15,000 markets with a leading service for CFD trading and forex.
loading

Compare up to 4 providers

Cara Therapeutics share price

Use our graph to track the performance of CARA stocks over time.

Cara Therapeutics shares at a glance

Information last updated 2021-05-07.
OpenUSD12.47
HighUSD12.76
LowUSD12.4
CloseUSD12.56
Previous closeUSD12.44
Change USD0.12
Change % 0.9646%
Volume 698,055
Information last updated 2021-05-07.
52-week rangeUSD12.16 - USD29.6473
50-day moving average USD22.5477
200-day moving average USD18.2442
Wall St. target priceUSD29.13
PE ratio 71.4124
Dividend yield N/A (0%)
Earnings per share (TTM) USD0.177

Cara Therapeutics price performance over time

Historical closes compared with the last close of $12.56

1 week (2021-04-29) -10.73%
1 month (2021-04-09) -56.97%
3 months (2021-02-09) -38.07%
6 months (2020-11-09) -13.44%
1 year (2020-05-08) -11.36%
2 years (2019-05-09) -34.85%
3 years (2018-05-09) -2.86%
5 years (2016-05-09) 129.20%

Is Cara Therapeutics under- or over-valued?

Valuing Cara Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cara Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cara Therapeutics's P/E ratio

Cara Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 71x. In other words, Cara Therapeutics shares trade at around 71x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Cara Therapeutics's EBITDA

Cara Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.6 million.

The EBITDA is a measure of a Cara Therapeutics's overall financial performance and is widely used to measure a its profitability.

Shorting Cara Therapeutics shares

There are currently 3.6 million Cara Therapeutics shares held short by investors – that's known as Cara Therapeutics's "short interest". This figure is 30.9% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting Cara Therapeutics shares can be evaluated.

Cara Therapeutics's "short interest ratio" (SIR)

Cara Therapeutics's "short interest ratio" (SIR) is the quantity of Cara Therapeutics shares currently shorted divided by the average quantity of Cara Therapeutics shares traded daily (recently around 1.6 million). Cara Therapeutics's SIR currently stands at 2.25. In other words for every 100,000 Cara Therapeutics shares traded daily on the market, roughly 2250 shares are currently held short.

However Cara Therapeutics's short interest can also be evaluated against the total number of Cara Therapeutics shares, or, against the total number of tradable Cara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cara Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cara Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.073% of the tradable shares (for every 100,000 tradable Cara Therapeutics shares, roughly 73 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cara Therapeutics.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site